drugset / Trial / NCT02290444

Effects of Acthar on Recovery From Cognitive Relapses in MS

NCT02290444

Phase 3 Completed 64 enrolled State University of New York at Buffalo
Non-randomizedParallel-groupOpen-labelSupportive care

Summary

The purpose of this study is to evaluate the effect of a medication called Acthar on recovery from multiple sclerosis-related relapses that impact cognition.

Timeline

Start
2013-08
Primary completion
2018-11-01
Completion
2018-11-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Acthar Peptide 5 ml Subcutaneous
Subject Acthar Peptide 80 iu Subcutaneous

Indications